Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Accounts Payables (2017 - 2025)

Tvardi Therapeutics' Accounts Payables history spans 12 years, with the latest figure at $3.2 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 47.26% to $3.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.2 million, a 47.26% increase, with the full-year FY2025 number at $3.2 million, up 47.26% from a year prior.
  • Accounts Payables hit $3.2 million in Q4 2025 for Tvardi Therapeutics, down from $4.1 million in the prior quarter.
  • Over the last five years, Accounts Payables for TVRD hit a ceiling of $26.3 million in Q3 2022 and a floor of $4000.0 in Q1 2025.
  • Historically, Accounts Payables has averaged $11.6 million across 5 years, with a median of $12.5 million in 2021.
  • Biggest five-year swings in Accounts Payables: surged 172.11% in 2023 and later plummeted 99.97% in 2025.
  • Tracing TVRD's Accounts Payables over 5 years: stood at $15.9 million in 2021, then tumbled by 39.45% to $9.6 million in 2022, then rose by 20.61% to $11.6 million in 2023, then tumbled by 81.13% to $2.2 million in 2024, then surged by 47.26% to $3.2 million in 2025.
  • Business Quant data shows Accounts Payables for TVRD at $3.2 million in Q4 2025, $4.1 million in Q3 2025, and $2.4 million in Q2 2025.